Publication:
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors

Simple item page
dc.contributor.authorJonathon Torchiaen_US
dc.contributor.authorBrian Golbournen_US
dc.contributor.authorShengrui Fengen_US
dc.contributor.authorKing Ching Hoen_US
dc.contributor.authorPatrick Sin-Chanen_US
dc.contributor.authorAlexandre Vasiljevicen_US
dc.contributor.authorJoseph D. Normanen_US
dc.contributor.authorPaul Guilhamonen_US
dc.contributor.authorLivia Garziaen_US
dc.contributor.authorNatalia R. Agamezen_US
dc.contributor.authorMei Luen_US
dc.contributor.authorTiffany S. Chanen_US
dc.contributor.authorDaniel Picarden_US
dc.contributor.authorPasqualino de Antonellisen_US
dc.contributor.authorDong Anh Khuong-Quangen_US
dc.contributor.authorAline C. Planelloen_US
dc.contributor.authorConstanze Zelleren_US
dc.contributor.authorDalia Barsyte-Lovejoyen_US
dc.contributor.authorLucie Lafay-Cousinen_US
dc.contributor.authorLouis Letourneauen_US
dc.contributor.authorMathieu Bourgeyen_US
dc.contributor.authorMan Yuen_US
dc.contributor.authorDeena M.A. Gendooen_US
dc.contributor.authorMisko Dzambaen_US
dc.contributor.authorMark Barszczyken_US
dc.contributor.authorTiago Medinaen_US
dc.contributor.authorAlexandra N. Riemenschneideren_US
dc.contributor.authorA. Sorana Morrissyen_US
dc.contributor.authorYoung Shin Raen_US
dc.contributor.authorVijay Ramaswamyen_US
dc.contributor.authorMarc Remkeen_US
dc.contributor.authorChristopher P. Dunhamen_US
dc.contributor.authorStephen Yipen_US
dc.contributor.authorHo keung Ngen_US
dc.contributor.authorJian Qiang Luen_US
dc.contributor.authorVivek Mehtaen_US
dc.contributor.authorSteffen Albrechten_US
dc.contributor.authorJose Pimentelen_US
dc.contributor.authorJennifer A. Chanen_US
dc.contributor.authorGino R. Somersen_US
dc.contributor.authorClaudia C. Fariaen_US
dc.contributor.authorLucia Roqueen_US
dc.contributor.authorMaryam Fouladien_US
dc.contributor.authorLindsey M. Hoffmanen_US
dc.contributor.authorAndrew S. Mooreen_US
dc.contributor.authorYin Wangen_US
dc.contributor.authorSeung Ah Choien_US
dc.contributor.authorJordan R. Hansforden_US
dc.contributor.authorDaniel Catchpooleen_US
dc.contributor.authorDiane K. Birksen_US
dc.contributor.authorNicholas K. Foremanen_US
dc.contributor.authorDoug Strotheren_US
dc.contributor.authorAlmos Klekneren_US
dc.contributor.authorLaszló Bognáren_US
dc.contributor.authorMiklós Garamien_US
dc.contributor.authorPéter Hauseren_US
dc.contributor.authorTibor Hortobágyien_US
dc.contributor.authorBeverly Wilsonen_US
dc.contributor.authorJuliette Hukinen_US
dc.contributor.authorAnne Sophie Carreten_US
dc.contributor.authorTimothy E. Van Meteren_US
dc.contributor.authorEugene I. Hwangen_US
dc.contributor.authorAmar Gajjaren_US
dc.contributor.authorShih Hwa Chiouen_US
dc.contributor.authorHideo Nakamuraen_US
dc.contributor.authorHelen Toledanoen_US
dc.contributor.authorIris Frieden_US
dc.contributor.authorDaniel Fultsen_US
dc.contributor.authorTakafumi Watayaen_US
dc.contributor.authorChris Fryeren_US
dc.contributor.authorDavid D. Eisenstaten_US
dc.contributor.authorKatrin Scheinemannen_US
dc.contributor.authorAdam J. Flemingen_US
dc.contributor.authorDonna L. Johnstonen_US
dc.contributor.authorJean Michauden_US
dc.contributor.otherUniversity of Torontoen_US
dc.contributor.otherHospital for Sick Children University of Torontoen_US
dc.contributor.otherOntario Cancer Institute University of Torontoen_US
dc.contributor.otherCHU de Lyonen_US
dc.contributor.otherMcGill Universityen_US
dc.contributor.otherAlberta Children's Hospitalen_US
dc.contributor.otherUniversity of Calgaryen_US
dc.contributor.otherAsan Medical Centeren_US
dc.contributor.otherThe University of British Columbiaen_US
dc.contributor.otherChinese University of Hong Kongen_US
dc.contributor.otherUniversity of Albertaen_US
dc.contributor.otherSanta Maria Hospital, Lisbonen_US
dc.contributor.otherInstituto Portugues de Oncologia de Francisco Gentil Lisboaen_US
dc.contributor.otherCincinnati Children's Hospital Medical Centeren_US
dc.contributor.otherUniversity of Colorado School of Medicineen_US
dc.contributor.otherUniversity of Queenslanden_US
dc.contributor.otherFudan Universityen_US
dc.contributor.otherSeoul National University College of Medicineen_US
dc.contributor.otherRoyal Children's Hospital, Melbourneen_US
dc.contributor.otherChildren's Hospital At Westmeaden_US
dc.contributor.otherDebreceni Egyetem Altalanos Orvostudomanyi Karen_US
dc.contributor.otherSemmelweis Egyetemen_US
dc.contributor.otherSzegedi Tudomanyegyetem (SZTE)en_US
dc.contributor.otherUniversity of Montrealen_US
dc.contributor.otherVirginia Commonwealth Universityen_US
dc.contributor.otherChildrens National Health Systemen_US
dc.contributor.otherSt. Jude Children's Research Hospitalen_US
dc.contributor.otherNational Yang-Ming University Taiwanen_US
dc.contributor.otherKumamoto Universityen_US
dc.contributor.otherChildren's Medical Center of Israelen_US
dc.contributor.otherHadassah University Medical Centreen_US
dc.contributor.otherUniversity of Utah, School of Medicineen_US
dc.contributor.otherShizuoka Children's Hospitalen_US
dc.contributor.otherMcMaster University, Faculty of Health Sciencesen_US
dc.contributor.otherChildren's Hospital of Eastern Ontario, Ottawaen_US
dc.contributor.otherLondon Health Sciences Centreen_US
dc.contributor.otherWestern Universityen_US
dc.contributor.otherDalhousie Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Nottinghamen_US
dc.contributor.otherAnn & Robert H. Lurie Children's Hospital of Chicagoen_US
dc.contributor.otherUniversity of California, San Franciscoen_US
dc.contributor.otherUniversity of Alabamaen_US
dc.contributor.otherJulius-Maximilians-Universität Würzburgen_US
dc.date.accessioned2018-12-11T02:05:47Z
dc.date.accessioned2019-03-14T08:03:18Z
dc.date.available2018-12-11T02:05:47Z
dc.date.available2019-03-14T08:03:18Z
dc.date.issued2016-12-12en_US
dc.description.abstract© 2016 Elsevier Inc. We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcriptional subtypes with different clinical outcomes; however, the mechanisms underlying therapeutic heterogeneity remained unclear. In this study, we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets. We found ATRTs segregated into three epigenetic subgroups with distinct genomic profiles, SMARCB1 genotypes, and chromatin landscape that correlated with differential cellular responses to a panel of signaling and epigenetic inhibitors. Significantly, we discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and suggest that these are promising therapies for this highly lethal ATRT subtype.en_US
dc.identifier.citationCancer Cell. Vol.30, No.6 (2016), 891-908en_US
dc.identifier.doi10.1016/j.ccell.2016.11.003en_US
dc.identifier.issn18783686en_US
dc.identifier.issn15356108en_US
dc.identifier.other2-s2.0-85004009880en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/42259
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85004009880&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleIntegrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumorsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85004009880&origin=inwarden_US

Files

Collections

Scopus 2016-2017